Cited 19 times in
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 김상겸 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김승현 | - |
dc.contributor.author | 김지형 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 박형순 | - |
dc.contributor.author | 서진석 | - |
dc.contributor.author | 신규호 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 이영한 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 한정우 | - |
dc.contributor.author | 허수진 | - |
dc.contributor.author | 허혁 | - |
dc.date.accessioned | 2019-09-20T07:45:34Z | - |
dc.date.available | 2019-09-20T07:45:34Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171045 | - |
dc.description.abstract | BACKGROUND: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). METHODS: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. RESULTS: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1-2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). CONCLUSIONS: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Karger | - |
dc.relation.isPartOf | Oncology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Hyung Soon Park | - |
dc.contributor.googleauthor | Su Jin Heo | - |
dc.contributor.googleauthor | Sang Kyum Kim | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Kyoo-Ho Shin | - |
dc.contributor.googleauthor | Seung Hyun Kim | - |
dc.contributor.googleauthor | Hyuk Hur | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Young Han Lee | - |
dc.contributor.googleauthor | Jin-Suck Suh | - |
dc.contributor.googleauthor | Joong-Bae Ahn | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.identifier.doi | 10.1159/000492597 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A00520 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00662 | - |
dc.contributor.localId | A00999 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A04576 | - |
dc.contributor.localId | A01916 | - |
dc.contributor.localId | A02086 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A02967 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04325 | - |
dc.contributor.localId | A04355 | - |
dc.contributor.localId | A04373 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 30336470 | - |
dc.identifier.url | https://www.karger.com/Article/FullText/492597 | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Pazopanib | - |
dc.subject.keyword | Second-line treatment | - |
dc.subject.keyword | Soft tissue sarcoma | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 김상겸 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 김승현 | - |
dc.contributor.affiliatedAuthor | 김지형 | - |
dc.contributor.affiliatedAuthor | 김효송 | - |
dc.contributor.affiliatedAuthor | 노성훈 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 박형순 | - |
dc.contributor.affiliatedAuthor | 서진석 | - |
dc.contributor.affiliatedAuthor | 신규호 | - |
dc.contributor.affiliatedAuthor | 안중배 | - |
dc.contributor.affiliatedAuthor | 이영한 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.contributor.affiliatedAuthor | 한정우 | - |
dc.contributor.affiliatedAuthor | 허수진 | - |
dc.contributor.affiliatedAuthor | 허혁 | - |
dc.citation.volume | 96 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 59 | - |
dc.citation.endPage | 69 | - |
dc.identifier.bibliographicCitation | Oncology, Vol.96(2) : 59-69, 2019 | - |
dc.identifier.rimsid | 64359 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.